# US 2017/0281531 A1 · Cranial delivery of pharmaceuticals

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281531 A1
- Document ID: US20170281531A1
- Status: Published application
- Kind: A1
- Application number: 15/627,894
- Filed: 2017-06-20
- Published: 2017-10-05
- Earliest claimed: 2013-03-15
- Assignees: Glia, LLC
- Applicants: Glia LLC
- Inventors: Kenneth I. Sawyer; Wei-wei Chang
- Web page: https://patentgrep.com/patent/US20170281531A1

## CPC

- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 31/57: substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K 31/658: {o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol}
- A61P 1/08: for nausea, cinetosis or vertigo; Antiemetics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/10: Anti-acne agents
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/22: Anxiolytics
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/00: Drugs for disorders of the senses
- A61P 27/02: Ophthalmic agents
- A61P 27/04: Artificial tears; Irrigation solutions
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 27/14: Decongestants or antiallergics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/22: for herpes viruses
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A method for rapid delivery of an active compound to innervate a cranial nerve of a subject. Also provided is a method for treating a disease or condition by topically applying a pharmaceutical composition to the face excluding the palpebral part of the eye, in an amount effective for treating the disease or condition.

## Claims

### Claim 1

A method for treating an ophthalmic disease or condition, the method comprising:
identifying a subject having the disease or condition, and
administering topically a topical progesterone composition to an area of the face of the subject not including the palpebral part of the eye,
wherein the ophthalmic disease or condition is selected from the group consisting of ocular inflammation, ocular allergy, ocular tissue damage, ocular redness, allergic conjunctivitis, corneal damage, eye discomfort resulting from iatrogenic causes, blepharitis, meibomian cyst, uveitis, punctate keratitis, retinitis, vision problems associated with dyslexia, Sjogren's syndrome, and ocular pain.

### Claim 2 (depends on 1)

The method of claim 1, wherein the area of the face not including the palpebral part of the eye is the forehead, the temple region, the upper cheek, or the bridge of the nose.

### Claim 3 (depends on 1)

The method of claim 1, wherein a dose of progesterone from 0.01 mg to 20 mg is administered.

### Claim 4 (depends on 2)

The method of claim 2, wherein a dose of progesterone from 0.01 mg to 20 mg is administered.

### Claim 5 (depends on 1)

The method of claim 1, wherein the ophthalmic disease or condition is eye discomfort resulting from iatrogenic causes, the iatrogenic causes being anti-histamines, glaucoma medications, immunosuppressants, laser eye surgery, cataract operations, or corneal transplants.

### Claim 6 (depends on 3)

The method of claim 3, wherein the ophthalmic disease or condition is eye discomfort resulting from iatrogenic causes, the iatrogenic causes being anti-histamines, glaucoma medications, immunosuppressants, laser eye surgery, cataract operations, or corneal transplants.

### Claim 7 (depends on 4)

The method of claim 4, wherein the ophthalmic disease or condition is eye discomfort resulting from iatrogenic causes, the iatrogenic causes being anti-histamines, glaucoma medications, immunosuppressants, laser eye surgery, cataract operations, or corneal transplants.

### Claim 8 (depends on 1)

The method of claim 1, wherein the ophthalmic disease or condition is shortened and sparse eyelashes and eyebrows resulting from madarosis.

### Claim 9 (depends on 3)

The method of claim 3, wherein the ophthalmic disease or condition is shortened and sparse eyelashes and eyebrows resulting from madarosis.

### Claim 10 (depends on 4)

The method of claim 4, wherein the ophthalmic disease or condition is shortened and sparse eyelashes and eyebrows resulting from madarosis.

### Claim 11

A method for treating dyslexia, the method comprising:
identifying a subject having dyslexia, and
administering topically a topical progesterone composition to an area of the face of the subject not including the palpebral part of the eye.

### Claim 12 (depends on 11)

The method of claim 11, wherein the area of the face not including the palpebral part of the eye is the forehead, the temple region, the upper cheek, or the bridge of the nose.

### Claim 13 (depends on 11)

The method of claim 11, wherein a dose of progesterone from 0.01 mg to 20 mg is administered.

### Claim 14 (depends on 12)

The method of claim 12, wherein a dose of progesterone from 0.01 mg to 20 mg is administered.

### Claim 15

A method for reducing behavioral and psychological symptoms associated with dementia, the method comprising:
identifying a subject having behavioral or psychological symptoms associated with dementia, and
administering topically a topical cannabinoid composition to an area of the face of the subject not including the palpebral part of the eye.

### Claim 16 (depends on 15)

The method of claim 15, wherein the area of the face not including the palpebral part of the eye is the forehead, the temple region, the upper cheek, or the bridge of the nose.

### Claim 17 (depends on 15)

The method of claim 15, wherein a dose of cannabinoid from 0.01 mg to 20 mg is administered.

### Claim 18 (depends on 17)

The method of claim 17, wherein the cannabinoid is dronabinol.

### Claim 19 (depends on 16)

The method of claim 16, wherein a dose of cannabinoid from 0.01 mg to 20 mg is administered.

### Claim 20 (depends on 19)

The method of claim 19, wherein the cannabinoid is dronabinol.